SI2011486T1 - Farmacevtski sestavki rifaksimina - Google Patents

Farmacevtski sestavki rifaksimina

Info

Publication number
SI2011486T1
SI2011486T1 SI200830741T SI200830741T SI2011486T1 SI 2011486 T1 SI2011486 T1 SI 2011486T1 SI 200830741 T SI200830741 T SI 200830741T SI 200830741 T SI200830741 T SI 200830741T SI 2011486 T1 SI2011486 T1 SI 2011486T1
Authority
SI
Slovenia
Prior art keywords
rifaximin
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
SI200830741T
Other languages
English (en)
Inventor
Harshal Anil Jahagirdar
Rajesh Kulkarni
Shirishkumar Kulkarni
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40091777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2011486(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of SI2011486T1 publication Critical patent/SI2011486T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SI200830741T 2007-07-06 2008-06-26 Farmacevtski sestavki rifaksimina SI2011486T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN968KO2007 2007-07-06
EP08252158 2008-06-23
EP08252198.0A EP2011486B2 (en) 2007-07-06 2008-06-26 Pharmaceutical compositions of rifaximin

Publications (1)

Publication Number Publication Date
SI2011486T1 true SI2011486T1 (sl) 2012-10-30

Family

ID=40091777

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200830741T SI2011486T1 (sl) 2007-07-06 2008-06-26 Farmacevtski sestavki rifaksimina

Country Status (8)

Country Link
EP (4) EP3714878B1 (sl)
CY (1) CY1113068T1 (sl)
DK (1) DK2011486T3 (sl)
ES (3) ES2798253T3 (sl)
HR (1) HRP20120665T1 (sl)
PL (1) PL2011486T5 (sl)
PT (1) PT2011486E (sl)
SI (1) SI2011486T1 (sl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
PL1698630T3 (pl) 2005-03-03 2014-12-31 Alfasigma Spa Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
EP2942053A1 (en) * 2007-07-06 2015-11-11 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
US20100204173A1 (en) 2008-10-02 2010-08-12 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
KR20120030542A (ko) * 2009-06-15 2012-03-28 샐릭스 파마슈티컬스 리미티드 리팍시민에 대한 전신 노출의 조절
KR102456997B1 (ko) * 2009-10-27 2022-10-19 루핀 리미티드 리팍시민의 고형 분산물
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
CN103228662B (zh) * 2010-07-12 2016-08-10 萨利克斯药品有限公司 利福昔明的制剂及其用途
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
IN2015DN01093A (sl) 2012-08-28 2015-06-26 Dsm Sinochem Pharm Nl Bv
ES2621557T3 (es) * 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
NZ723571A (en) 2014-05-12 2020-02-28 Alfasigma Spa New solvated crystal form of rifaximin, production, compositions and uses thereof
ES2929768T3 (es) * 2016-09-30 2022-12-01 Salix Pharmaceuticals Inc Formas sólidas de dispersión de rifaximina
US11052071B2 (en) 2017-04-26 2021-07-06 Sandoz Ag Oral dosage form comprising rifaximin in form beta
US11129862B2 (en) 2017-08-30 2021-09-28 Johnson & Johnson Consumer Inc. Ophthalmic compositions
CN108658673A (zh) * 2018-06-27 2018-10-16 安徽瑞然生物药肥科技有限公司 一种用于缓释肥料的包膜材料及其制备方法
CN109021187B (zh) * 2018-08-24 2019-09-06 中山大学 玉米醇溶蛋白-聚磺基甜菜碱两亲性缀合物及其制备方法与应用
CN109663150B (zh) * 2018-12-29 2022-01-14 广州贝奥吉因生物科技股份有限公司 一种心肌修复水凝胶材料及其制备方法
WO2020208140A1 (en) 2019-04-12 2020-10-15 Sandoz Ag Rifaximin-containing granules
MX2022003481A (es) * 2019-09-24 2022-04-25 Bausch Health Ireland Ltd Formulaciones liquidas de rifaximina.
CN111317824B (zh) * 2020-02-29 2022-04-12 复旦大学 一种载多肽药物的口服纳米制剂及其制备方法
EP4171520A1 (en) * 2020-06-26 2023-05-03 Bausch Health Ireland Limited Targeted release rifaximin compositions
WO2023067485A1 (en) * 2021-10-19 2023-04-27 Zydus Lifesciences Limited Pharmaceutical combinations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1253711B (it) * 1991-12-17 1995-08-23 Alfa Wassermann Spa Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali
IT1264494B1 (it) † 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
ITMI20041295A1 (it) † 2004-06-25 2004-09-25 Cosmo Spa Composizioni farmaceutiche antimicrobiche orali
US20060045865A1 (en) † 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina

Also Published As

Publication number Publication date
EP2837378A1 (en) 2015-02-18
CY1113068T1 (el) 2016-04-13
PL2011486T5 (pl) 2016-09-30
ES2389358T3 (es) 2012-10-25
PT2011486E (pt) 2012-08-24
ES2389358T5 (es) 2016-01-19
EP2011486B2 (en) 2015-08-12
PL2011486T3 (pl) 2013-01-31
ES2905795T3 (es) 2022-04-12
EP2420226A1 (en) 2012-02-22
EP2011486B1 (en) 2012-05-23
HRP20120665T1 (hr) 2012-10-31
EP2011486A1 (en) 2009-01-07
ES2798253T3 (es) 2020-12-10
EP3714878A1 (en) 2020-09-30
EP2420226B1 (en) 2020-03-04
EP3714878B1 (en) 2022-01-19
DK2011486T3 (da) 2012-09-03

Similar Documents

Publication Publication Date Title
ZA201000437B (en) Pharmaceutical compositions of rifaximin
PL2011486T3 (pl) Farmaceutyczne kompozycje rifaksyminy
IL247741A0 (en) pharmaceutical preparations
ZA200900347B (en) Preparation of pharmaceutical compositions
EP2222313A4 (en) PHARMACEUTICAL COMPOSITIONS
IL199941A0 (en) Compositions of stable tiacumicins
GB0610322D0 (en) Novel pharmaceutical compositions
GB0608724D0 (en) Novel Pharmaceutical Compositions
SI2966175T1 (sl) Farmacevtski sestavki vsebujoči korteksolon-17-alfa-propionat
EP2146695A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0709811D0 (en) Pharmaceutical compositions
PL2002825T3 (pl) Kompozycje farmaceutyczne zawierające orlistat
GB0707127D0 (en) Pharmaceutical compositions
GB0716907D0 (en) Pharmaceutical powder compositions
GB0712454D0 (en) Pharmaceutical compositions
GB2454923B (en) Pharmaceutical compositions
IL201394A0 (en) Niacin - based pharmaceutical compositions
HU0700755D0 (en) Pharmaceutical compositions containing capsaicionid
GB0713794D0 (en) Novel pharmaceutical compositions
GB0704749D0 (en) Novel pharmaceutical compositions
GB0701368D0 (en) Novel pharmaceutical compositions
GB0701367D0 (en) Novel pharmaceutical compositions
GB0701364D0 (en) Novel pharmaceutical compositions
GB0709603D0 (en) Pharmaceutical compositions
GB0706657D0 (en) Pharmaceutical compositions